Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q26851608)
Watch
English
Combining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapy
scientific article
In more languages
edit
Statements
instance of
scholarly article
2 references
stated in
PubMed
stated in
Europe PubMed Central
PMC publication ID
3444804
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22410456%20AND%20SRC:MED&resulttype=core&format=json
retrieved
25 January 2020
title
Combining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapy
(English)
2 references
stated in
PubMed
stated in
Europe PubMed Central
PMC publication ID
3444804
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22410456%20AND%20SRC:MED&resulttype=core&format=json
retrieved
25 January 2020
main subject
immunotherapy
1 reference
based on heuristic
inferred from title
prostate cancer
1 reference
based on heuristic
inferred from title
author
Emmanuel S Antonarakis
series ordinal
1
1 reference
stated in
Europe PubMed Central
PMC publication ID
3444804
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22410456%20AND%20SRC:MED&resulttype=core&format=json
retrieved
25 January 2020
author name string
Charles G Drake
series ordinal
2
1 reference
stated in
Europe PubMed Central
PMC publication ID
3444804
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22410456%20AND%20SRC:MED&resulttype=core&format=json
retrieved
25 January 2020
language of work or name
English
1 reference
stated in
PubMed
publication date
1 May 2012
1 reference
stated in
Europe PubMed Central
PMC publication ID
3444804
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22410456%20AND%20SRC:MED&resulttype=core&format=json
retrieved
25 January 2020
published in
Current Opinion in Oncology
2 references
stated in
PubMed
stated in
Europe PubMed Central
PMC publication ID
3444804
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22410456%20AND%20SRC:MED&resulttype=core&format=json
retrieved
25 January 2020
volume
24
2 references
stated in
PubMed
stated in
Europe PubMed Central
PMC publication ID
3444804
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22410456%20AND%20SRC:MED&resulttype=core&format=json
retrieved
25 January 2020
issue
3
2 references
stated in
PubMed
stated in
Europe PubMed Central
PMC publication ID
3444804
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22410456%20AND%20SRC:MED&resulttype=core&format=json
retrieved
25 January 2020
page(s)
258-265
1 reference
stated in
Europe PubMed Central
PMC publication ID
3444804
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22410456%20AND%20SRC:MED&resulttype=core&format=json
retrieved
25 January 2020
cites work
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3444804
retrieved
7 April 2017
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3444804
retrieved
7 April 2017
Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3444804
retrieved
7 April 2017
Sipuleucel-T immunotherapy for castration-resistant prostate cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3444804
retrieved
7 April 2017
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3444804
retrieved
7 April 2017
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3444804
retrieved
7 April 2017
Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3444804
retrieved
7 April 2017
Abiraterone and increased survival in metastatic prostate cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3444804
retrieved
7 April 2017
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3444804
retrieved
7 April 2017
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3444804
retrieved
7 April 2017
The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3444804
retrieved
28 September 2017
Prostate cancer immunotherapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3444804
retrieved
28 September 2017
Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3444804
retrieved
28 September 2017
DNA vaccines for the treatment of prostate cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3444804
retrieved
28 September 2017
DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3444804
retrieved
28 September 2017
Monoclonal antibodies: versatile platforms for cancer immunotherapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3444804
retrieved
28 September 2017
Current status of immunological therapies for prostate cancer.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3444804
retrieved
28 September 2017
Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3444804
retrieved
28 September 2017
Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3444804
retrieved
28 September 2017
Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3444804
retrieved
28 September 2017
Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3444804
retrieved
28 September 2017
Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3444804
retrieved
28 September 2017
Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3444804
retrieved
28 September 2017
Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3444804
retrieved
28 September 2017
The anticancer immune response: indispensable for therapeutic success?
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3444804
retrieved
28 September 2017
Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3444804
retrieved
28 September 2017
Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3444804
retrieved
28 September 2017
Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3444804
retrieved
28 September 2017
T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3444804
retrieved
28 September 2017
Expanding treatment options for metastatic prostate cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3444804
retrieved
31 May 2018
Androgen ablation augments prostate cancer vaccine immunogenicity only when applied after immunization
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3444804
retrieved
31 May 2018
Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3444804
retrieved
31 May 2018
Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/22410456
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Identifiers
DOI
10.1097/CCO.0B013E32835205A0
1 reference
stated in
Europe PubMed Central
PMC publication ID
3444804
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22410456%20AND%20SRC:MED&resulttype=core&format=json
retrieved
25 January 2020
PMC publication ID
3444804
2 references
stated in
PubMed
stated in
Europe PubMed Central
PMC publication ID
3444804
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22410456%20AND%20SRC:MED&resulttype=core&format=json
retrieved
25 January 2020
PubMed publication ID
22410456
2 references
stated in
PubMed
stated in
Europe PubMed Central
PMC publication ID
3444804
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22410456%20AND%20SRC:MED&resulttype=core&format=json
retrieved
25 January 2020
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
